Mirum 10-Q: Q3 Sales $185.7M, $898.1M Nine-Month Loss on Bluejay IPR&D Charge
MIRM sits 38% above its 52-week low of $63.232.
Summary
Mirum's Q3 10-Q details a $898.1 million nine-month net loss driven by a $756.2 million Bluejay IPR&D charge, $500.5 million of cash and investments, and a $749.0 million convertible note stack after the May 2026 refinancing.
Key Events · Earnings and Guidance · MIRM
-
Q3 Product Sales Up 40%
Net product sales were $185.7 million versus $133.0 million a year earlier, with LIVMARLI at $133.4 million and Bile Acid Medicines at $52.3 million.
-
Bluejay Charge Drives Nine-Month Loss
Acquired IPR&D expense of $756.2 million — $726.3 million of it from the January 2026 Bluejay acquisition — pushed the nine-month net loss to $898.1 million, or $14.35 per basic share.
-
Cash Covers At Least Twelve Months
Unrestricted cash, cash equivalents and investments totaled $500.5 million at September 30, 2026; management states this funds operations for at least the next twelve months.
-
Convertible Debt Refinanced
Mirum issued $690.0 million of 0.00% 2032 notes (net proceeds ~$672.0 million) and retired $237.2 million of 2029 notes for $474.7 million cash plus 3,220,529 shares, then repurchased another $20.0 million of 2029 notes for $62.0 million in September; $749.0 million principal remains outstanding.
Analysis · MIRM · Life Sciences
The headline numbers were already out in this morning's 8-K, but the 10-Q fills in what the press release did not. A $756.2 million acquired IPR&D charge from the January Bluejay deal drives the $898.1 million nine-month net loss, and the company still holds $500.5 million of unrestricted cash and investments — enough, management says, to fund operations for at least twelve months. After the May 2026 refinancing, the balance sheet now carries $749.0 million of convertible notes; that refinancing swapped most of the 4.00% 2029 notes for $690.0 million of 0.00% 2032 notes at a $138.94 conversion price, cutting cash interest expense. The other item worth flagging is the LIVMARLI patent fight: four ANDA challenges are now consolidated with a Markman hearing in July 2027 and trial in September 2028, and the 30-month stays block generic oral-solution launches until March 2029. Nothing here changes the growth story — product sales rose 40% to $185.7 million — but the loss optics and the litigation calendar are the details a reader of the press release alone would miss.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MIRM was trading at $87.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.7B. The 52-week trading range was $63.23 to $130.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.